Abstract:
Se proporcionan procedimientos, programas y sistemas para eliminación de ruido en una secuencia de imágenes producida por un procedimiento de generación de imágenes con datos volumétricos utilizando un algoritmo de trazado de caminos de rayos de luz en medios participativos. Cada imagen de la secuencia comprende píxeles y el algoritmo de trazado de caminos produce muestras de camino para cada píxel. Estos procedimientos comprenden para cada píxel de una imagen actual de la secuencia: re-proyectar temporalmente el píxel dependiendo de un vector de movimiento para obtener un color promedio acumulado y un modelo predictivo del píxel; promediar un color del píxel con el color promedio acumulado para obtener un color promedio acumulado actualizado; incluir el color promedio acumulado actualizado en un vector de características; y determinar un color final del píxel actualizando el modelo predictivo dependiendo del vector de características actualizado y obteniendo dicho color final del modelo predictivo actualizado.
Abstract:
The present invention relates to compounds of formula (I): AA1-AA2-D-Ile-AA3-D-Met-D-Tyr-D-Ala-D-Tyr-D-Val-D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2 or a pharmaceutically acceptable salts thereof, to processes for their obtention and to their therapeutic indications.
Abstract:
Described herein is a gene construct comprising a nucleotide sequence encoding insulin, for use in the treatment and/or prevention of neuroinflammation, neurodegeneration and/or cognitive decline, or a disease or condition associated therewith.
Abstract:
The present invention provides a method for the in vitro diagnosis of dementia with Lewy bodies in a human patient comprising the step of determining the amount of transcripts SNCAtv3 (SEQ ID NO: 3) and SNCAtv2 (SEQ ID NO: 2) of the human alpha-synuclein gene (SNCA) in a biological sample obtained from the patient, wherein when the amount of both transcripts determined for the patient is reduced with respect to a reference value, this is indicative of the presence of dementia with Lewy bodies in the patient. The invention further provides means to determine the amount of said transcripts, as well as a method to stablish the response of a patient which has been diagnosed with dementia with Lewy bodies to a medical regime for its treatment by determining the amount of transcripts SNCAtv3 and SNCAtv2 in a biological sample from the patient before and after the treatment.
Abstract translation:本发明提供了一种用于人类患者路易体痴呆体外诊断的方法,其包括测定人α的转录物SNCAtv3(SEQ ID NO:3)和SNCAtv2(SEQ ID NO:2)的量的步骤 - 来自患者的生物样品中的突触核蛋白基因(SNCA),其中当相对于参考值减少为患者确定的两个转录物的量减少时,这表明患者中路易体的痴呆的存在。 本发明还提供了确定所述转录物的量的方法,以及通过确定转录物量SNCAtv3和SNCAtv2来确定已被诊断患有路易体性痴呆的患者对其治疗的医疗方案的反应的方法 在患者治疗前后的生物样品中。
Abstract:
The invention provides an in vitro method for the diagnosis of dementia with Lewy bodies comprising detecting, in a biological sample from a subject, at least one variation in SEQ ID NO: 14, or alternatively at least one variation in SEQ ID NO: 15, or alternatively at least one variation in SEQ ID NO: 16, wherein SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16 are comprised within position 175.989.261 to position 176.003.107 in Homo sapiens chromosome 5 according to HapMap data release 28 (SEQ ID NO: 1). The invention also provides means for detecting the above variations and a method for recommending to initiate a medical regime for the treatment of DLB in a subject based on detecting the above variations. In particular, the provided method is for the in vitro diagnosis of pure dementia with Lewy bodies.
Abstract translation:本发明提供了用于诊断路易体痴呆症的体外方法,包括在来自受试者的生物样品中检测SEQ ID NO:14中的至少一个变体,或者SEQ ID NO:14中至少一个变体, 或者可选地,SEQ ID NO:16中的至少一个变体,其中SEQ ID NO:14,SEQ ID NO:15和SEQ ID NO:16包含在位置175.989.261中,以在智人5号染色体中位置176.003.107根据 HapMap数据版本28(SEQ ID NO:1)。 本发明还提供了用于检测上述变化的方法以及用于基于检测上述变化来推荐用于开始用于治疗受试者的DLB的医疗方案的方法。 特别地,所提供的方法是用路易体纯体痴呆的体外诊断。
Abstract:
The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors. The invention also relates to pharmaceutical compositions comprising said vectors.
Abstract:
In a first aspect, the present invention provides a method for detecting defects on yarns arranged substantially in parallel from a grey scale image (10) of the yarns, said grey scale image being divided into one or more image sections; the method comprising for each image section (10): calculating a restrictive threshold and a less restrictive threshold from the image section (10); obtaining a restrictive image section (11) by applying the restrictive threshold to the image section (10); obtaining a less restrictive image section (12) by applying the less restrictive threshold to the image section (10). Said method further comprises: obtaining a differential image (13) from the obtained restrictive image sections (11) and the obtained less restrictive image sections (12); and detecting defects on the yarns by comparing (15) the pixels (16) of the differential image (13) representing existence of difference with predetermined defect patterns (14).
Abstract:
The present invention provides a biosafe and useful vector to transfer genetic material to CD 14+ mononuclear cells (monocytes and monocyte-derived macrophages) in an efficient and specific manner. The embodiment of the invention makes use of the chimeric human adenovirus vectors 5 carrying the short fiber of enterotropic Ad40 to transfer genetic material to the target CD14+ mononuclear cells.
Abstract:
The present invention relates to an encoded microparticle for labeling an isolated cell or an isolated embryo characterized in that it is made of a biocompatible material and its external shape comprises a code by which it can be identified. The use of an encoded microparticle for labeling and/or tracking isolated biological material. A method of tracking an encoded microparticle in or attached to an isolated cell or embryo using an optical microscope, preferably an inverted optical microscope with an objective substantially between 20X -100X.
Abstract:
La invención aporta un método para predecir un trastorno hemorrágico en un paciente que comprende determinar en una muestra de dicho paciente los niveles de una amino oxidasa y, en particular, de VAP-1. Asimismo, la invención proporciona composiciones farmacéuticas que comprenden un inhibidor de una amino oxidasa y un agente antitrombótico así como el uso de un inhibidor de una amino oxidasa para el tratamiento de trastornos hemorrágicos.